Merck & Co., Inc. (MRK) Scheduled to Post Quarterly Earnings on Thursday

Merck & Co., Inc. (NYSE:MRK) will announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of $2.12 per share for the quarter. Merck & Co., Inc. has set its FY 2024 guidance at 8.440-8.590 EPS and its FY24 guidance at $8.44 to $8.59 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.12. The business had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 EPS. On average, analysts expect Merck & Co., Inc. to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $126.94 on Tuesday. The firm has a market capitalization of $321.54 billion, a P/E ratio of 906.71, a P/E/G ratio of 1.63 and a beta of 0.38. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The stock has a 50 day moving average price of $126.21 and a two-hundred day moving average price of $115.35. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25.

Analyst Ratings Changes

MRK has been the topic of several analyst reports. Barclays lifted their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Berenberg Bank lifted their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. StockNews.com upgraded shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Finally, UBS Group upped their price objective on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $131.25.

Insider Buying and Selling

In other news, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the completion of the sale, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Merck & Co., Inc. news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.